Viking Therapeutics price target lowered to $96 from $109 at B. Riley
B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains ...
Viking Therapeutics price target lowered to $70 from $120 at Maxim
Maxim lowered the firm’s price target on Viking Therapeutics (VKTX) to $70 from $120 and keeps a Buy rating on the shares after the company’s ...
The M&A boom of 2025 is just getting started - and here are 5 takeover targets
Stock investors may look back at 2025 as the year of the takeover - one that delivered sizeable gains. "It's going to be a big year," Calamos Investments senior portfolio manager Brandon Nelson ...
The Pharma Letter17h
Viking sails ahead with pivotal trial and billion dollar cash pile
San Diegan biotech Viking Therapeutics (Nasdaq: VKTX) has announced plans to initiate late-stage clinical trials for its ...
Investor's Business Daily on MSN17h
Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why.
Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...
Viking Therapeutics Reports Q4 2024 Financial Results, Advances VK2735 Trials
Viking Therapeutics ( VKTX, Financials) reported its fourth-quarter and full-year 2024 financial results, highlighting ...